Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) insider James Patrick Tursi bought 4,750 shares of the business’s stock in a transaction that occurred on Wednesday, March 15th. The stock was acquired at an average cost of $2.11 per share, with a total value of $10,022.50. Following the completion of the acquisition, the insider now owns 184,118 shares of the company’s stock, valued at approximately $388,488.98. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) opened at 1.61 on Monday. The company has a 50 day moving average of $3.60 and a 200-day moving average of $4.49. Aralez Pharmaceuticals Inc has a 12-month low of $1.51 and a 12-month high of $6.80. The stock’s market capitalization is $105.75 million.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Monday, March 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.11. The company earned $20 million during the quarter, compared to analyst estimates of $21.86 million. Aralez Pharmaceuticals had a negative net margin of 211.76% and a negative return on equity of 65.67%. Aralez Pharmaceuticals’s revenue for the quarter was up 233.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.40) EPS. On average, equities research analysts forecast that Aralez Pharmaceuticals Inc will post ($1.34) earnings per share for the current year.
A number of large investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd bought a new stake in Aralez Pharmaceuticals during the fourth quarter worth about $103,000. Shufro Rose & Co. LLC raised its stake in Aralez Pharmaceuticals by 30.3% in the third quarter. Shufro Rose & Co. LLC now owns 21,487 shares of the company’s stock worth $104,000 after buying an additional 5,000 shares in the last quarter. J. Goldman & Co LP bought a new stake in Aralez Pharmaceuticals during the fourth quarter worth about $198,000. Nwam LLC bought a new stake in Aralez Pharmaceuticals during the third quarter worth about $228,000. Finally, FNY Managed Accounts LLC raised its stake in Aralez Pharmaceuticals by 13.5% in the third quarter. FNY Managed Accounts LLC now owns 59,000 shares of the company’s stock worth $286,000 after buying an additional 7,000 shares in the last quarter. 44.01% of the stock is currently owned by institutional investors.
Separately, Chardan Capital cut their target price on shares of Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating for the company in a report on Wednesday, March 15th.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with our FREE daily email newsletter.